Literature DB >> 6786404

The beneficial actions of bepridil in acute myocardial infarction in anaesthetized dogs.

R J Marshall, A W Muir.   

Abstract

1 When administered intravenously shortly before acute coronary ligation in dogs anaesthetized with chloralose, bepridil (5 mg/kg) produced immediate and transient falls in coronary and systemic vascular resistance which were accompanied by marked decreases in myocardial oxygen extraction. These effects were followed by sustained decreases in heart rate and myocardial oxygen consumption. 2 This dose of bepridil reduced the number of premature ventricular beats and abolished fibrillation induced by coronary artery ligation without modifying the haemodynamic or metabolic consequences (lactate production) of myocardial ischaemia. 3 When administered 1.5-2 h after ligation, bepridil did not compromise the critical perfusion of the acutely ischaemic zone but reduced the lactate production and ST-segment elevation in the ischaemic zone. 4 These results suggest that bepridil may be a useful drug in the chronic treatment of angina pectoris and in this respect may possess advantages over beta-adrenoceptor antagonists.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6786404      PMCID: PMC2071673          DOI: 10.1111/j.1476-5381.1981.tb10445.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  17 in total

1.  Comparative effects of propranolol and practolol in the early stages of experimental canine myocardial infarction.

Authors:  R J Marshall; J R Parratt
Journal:  Br J Pharmacol       Date:  1976-06       Impact factor: 8.739

2.  Prevention of ventricular fibrillation induced by coronary ligation.

Authors:  A J Kaumann; P Aramendía
Journal:  J Pharmacol Exp Ther       Date:  1968-12       Impact factor: 4.030

3.  Haemodynamic and myocardial effects of hyperbaric oxygen in dogs subjected to haemorrhage.

Authors:  I M Ledingham; J R Parratt; G Smith; J P Vance
Journal:  Cardiovasc Res       Date:  1971-07       Impact factor: 10.787

4.  Some membrane interactions with bepridil, a new antianginal agent.

Authors:  C Labrid; A Grosset; G Dureng; J Mironneau; P Duchene-Marullaz
Journal:  J Pharmacol Exp Ther       Date:  1979-12       Impact factor: 4.030

5.  Systolic and diastolic pressure gradients within the left ventricular wall.

Authors:  P D Stein; M Marzilli; H N Sabbah; T Lee
Journal:  Am J Physiol       Date:  1980-05

6.  Blockade of myocardial slow channels by bepridil (CERM-1978).

Authors:  S Vogel; R Crampton; N Sperelakis
Journal:  J Pharmacol Exp Ther       Date:  1979-09       Impact factor: 4.030

7.  Antidysrhythmic and electrophysiological effects of a new antianginal agent, bepridil.

Authors:  K A Kane; E Winslow
Journal:  J Cardiovasc Pharmacol       Date:  1980       Impact factor: 3.105

8.  Cardiovascular pharmacology of bepridil (1[3 isobutoxy 2 (benzylphenyl) amino] propyl pyrrolidine hydrochloride) a new potential anti-anginal compound.

Authors:  D Cosnier; P Duchenne-Marullaz; G Rispat; G Streichenberger
Journal:  Arch Int Pharmacodyn Ther       Date:  1977-01

9.  Effect of drugs on conduction delay and incidence of ventricular arrhythmias induced by acute coronary occlusion in dogs.

Authors:  V Elharrar; W E Gaum; D P Zipes
Journal:  Am J Cardiol       Date:  1977-04       Impact factor: 2.778

10.  The effects of disopyramide phosphate on early post-coronary artery ligation dysrhythmias and on epicardial ST-segment elevation in anaesthetized dogs.

Authors:  R J Marshall; J R Parratt
Journal:  Br J Pharmacol       Date:  1979-06       Impact factor: 8.739

View more
  9 in total

1.  Effects of bepridil and lidocaine on the intraventricular conduction in acutely ischaemic and infarcted canine myocardium.

Authors:  H Hashimoto; N Satoh; M Nakashima
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1990-12       Impact factor: 3.000

2.  Effects of the calcium entry blocker bepridil on repolarizing and pacemaker currents in sheep cardiac Purkinje fibres.

Authors:  F Berger; U Borchard; D Hafner
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1989-06       Impact factor: 3.000

3.  Bepridil and cetiedil. Vasodilators which inhibit Ca2+-dependent calmodulin interactions with erythrocyte membranes.

Authors:  P Agre; D Virshup; V Bennett
Journal:  J Clin Invest       Date:  1984-09       Impact factor: 14.808

4.  Lidoflazine in the early stages of acute myocardial ischaemia.

Authors:  S J Coker; O Fagbemi; J R Parratt
Journal:  Br J Pharmacol       Date:  1982-06       Impact factor: 8.739

5.  Effects of bepridil on the electrophysiological properties of guinea-pig ventricular muscles.

Authors:  T Anno; T Furuta; M Itho; I Kodama; J Toyama; K Yamada
Journal:  Br J Pharmacol       Date:  1984-04       Impact factor: 8.739

Review 6.  Bepridil. A review of its pharmacological properties and therapeutic use in stable angina pectoris.

Authors:  L M Hollingshead; D Faulds; A Fitton
Journal:  Drugs       Date:  1992-11       Impact factor: 9.546

7.  Comparative clinical efficacy of bepridil, propranolol and placebo in patients with chronic stable angina.

Authors:  A P Rae; J M Beattie; T D Lawrie; I Hutton
Journal:  Br J Clin Pharmacol       Date:  1985-03       Impact factor: 4.335

8.  Effects of Org 7797 on early, late and inducible arrhythmias following coronary artery occlusion in rats and dogs.

Authors:  E Winslow; J K Campbell; E Barron; R J Marshall; A W Muir
Journal:  Br J Pharmacol       Date:  1991-12       Impact factor: 8.739

Review 9.  Bepridil: a pharmacological reappraisal of its potential beneficial effects in angina and tissue protection following ischemia.

Authors:  R Massingham; P A Van Zwieten
Journal:  Cardiovasc Drugs Ther       Date:  1989-10       Impact factor: 3.727

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.